Bio-Techne Collaborates on $2 Million Initiative to Advance Cell Therapy Manufacturing in California

Bio-Techne Partners in Groundbreaking Cell Therapy Initiative

In a significant move to enhance California's position in the field of cell and gene therapy (CGT) manufacturing, Bio-Techne Corporation collaborates with ScaleReady, Wilson Wolf Manufacturing, and CellReady to announce the awarding of eight G-Rex Grants. This initiative, supported by the California Institute for Regenerative Medicine (CIRM) Manufacturing Network, allocates nearly $2 million to boost non-profit academic Good Manufacturing Practice (GMP) facilities in the state. With a focus on fostering industry partnerships and supporting innovative research, the initiative aims to fortify California's leadership in the burgeoning CGT sector.

The G-Rex Grants play a pivotal role in advancing cost-effective cell therapy manufacturing platforms, as emphasized by Dr. Shyam Patel, CIRM’s Associate Vice President of Preclinical Development. These grants not only provide financial support but also facilitate collaborative efforts among academic institutions and industry stakeholders. Notable projects include Dr. Dan Kaufman's initiative at UC San Diego to develop a novel G-Rex® production system for virus-like particles, which is crucial for immune cell engineering. Similarly, Dr. Taby Ahsan of City of Hope receives funding to enhance CAR-T cell therapy production, while Dr. Steve Feldman from Stanford Medicine secures a grant for developing CAR-T therapies with the first to enter clinical trials for pediatric neuroblastoma and medulloblastoma.

The G-Rex manufacturing platform's widespread adoption across California's academic institutions highlights its essential role in driving innovation within the CGT landscape. By enabling researchers to develop and refine cell therapies, the grants contribute to the acceleration of clinical trials and the achievement of regulatory approvals. This collaborative effort not only supports the research community but also positions Bio-Techne as a key player in the evolution of effective cell therapy solutions, ultimately benefiting patients in need.

In addition to the grants, the initiative represents a strategic alignment of resources that enhances Bio-Techne's visibility and influence in the regenerative medicine sector. By partnering with leading academic institutions, the company solidifies its commitment to advancing cutting-edge technologies in cell therapy manufacturing. This collaboration is expected to lead to breakthroughs that will improve therapeutic outcomes and expand the availability of innovative treatment options.

The G-Rex Grants and the partnerships formed through this initiative underscore the importance of collaborative efforts in the rapidly evolving field of cell and gene therapy. As California continues to lead in this domain, Bio-Techne's involvement not only exemplifies its dedication to innovation but also reinforces the critical role of industry partnerships in achieving significant advancements in healthcare.